|
Age (yrs)
|
13.6 (2.2)
|
13.6 (2.1)
|
13.5 (2.6)
|
|
Female sex, n (%)
|
50 (85)
|
30 (81)
|
50 (85)
|
|
Height (cm)
|
157.6 (12.5)
|
158.5 (13.0)
|
160.8 (12.3)
|
|
Weight (kg)
|
48.3 (11.8)
|
49.5 (12.7)
|
53.1 (15.2)
|
|
BMI (kg/m2)
|
19.2 (3.0)
|
19.4 (3.3)
|
20.1 (3.5)
|
|
Waist circumference (cm)
|
70.5 (9.8)
|
70.2 (8.9)
|
69.3 (9.2)
|
|
Pubertal status (pre-, mid-, and postpubertal %)
|
24/61/15
|
22/65/13
|
17/68/15
|
|
NRS current pain (0–10), n (%) score > 0
|
23 (38)
|
16 (43)
|
18 (30)
|
|
NRS pain previous week (0–10)
|
1.0 (0.0–3.0)
|
1.0 (1.0–3.5)
|
1.0 (0.0–3.0)
|
|
NRS fatigue previous week (0–10)
|
3 (2.0–6.0)
|
3.0 (2.0–6.0)
|
3.0 (1.0–5.0)
|
|
Oligo/poly, n (%)
|
30 (51) / 29 (49)
|
18 (49) / 19 (51)
|
NA
|
|
Disease duration (yrs)
|
7.5 (3.8)
|
7.5 (3.9)
|
NA
|
|
JADAS 71 (0–101)
|
3.2 (1.1–4.8)
|
3.0 (1.0–4.7)
|
NA
|
|
CHAQ score (0–3)
|
0.0 (0.0–0.3)
|
0.1 (0.0–0.4)
|
NA
|
|
Off medication, n (%)
|
12 (20)
|
9 (24)
|
NA
|
|
Synthetic DMARDs, n (%)
|
39 (66)
|
24 (65)
|
NA
|
|
Biologic DMARDs, n (%)
|
25 (42)
|
15 (41)
|
NA
|
|
Active disease, n (%)
|
20 (34)
|
12 (32)
|
NA
|
|
Inactive disease, n (%)
|
39 (66)
|
25 (68)
|
NA
|
